News & Events

Press Releases

Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis

21 February 2025/by Leyla Karabekmez

Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients

13 November 2024/by Freddie Kerner

Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma

7 October 2024/by Freddie Kerner

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies

27 August 2024/by Freddie Kerner

Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies

9 July 2024/by Freddie Kerner

Microbiotica announces clinical trial collaboration with MSD to evaluate MB097 in combination with KEYTRUDA^® (pembrolizumab) in a phase 1b clinical trial in melanoma

12 April 2023/by immunocity

Microbiotica announces transition of leadership

29 November 2022/by immunocity

Microbiotica to present at key industry conferences in Q3 2022

20 June 2022/by immunocity

Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic

5 April 2022/by immunocity